{
    "nctId": "NCT01975363",
    "briefTitle": "Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer",
    "officialTitle": "Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "Determine the adherence, tolerability and safety of two doses of nanoemulsion curcumin (NEC)in women at high risk for developing breast cancer.",
    "eligibilityCriteria": "INCLUSION CRITERIA:\n\n* Increased risk for breast cancer based on family history, personal history\n* Normal mammogram, clinical breast examination in the past 12 months\n* \\>1 year from pregnancy, lactation or chemotherapy\n* Body mass index (BMI) between 25 - 40\n\nEXCLUSION CRITERIA:\n\n* Concurrent malignancy or metastatic malignancy of any kind\n* Ongoing chemotherapy, radiation therapy, or other cancer-related treatment\n* History of a bleeding tendency or current use of Coumadin or other anticoagulants\n* Current or previous history of liver, gastrointestinal, hematopoietic, cardiac or renal disease, viral, bacterial, atypical or fungal infections of any organ system and human immunodeficiency virus (HIV) infection\n* Pregnant or lactating women\n* Concurrent use of hormonal contraception or hormone replacement therapy\n* Concurrent use of immunosuppressant medications\n* Concurrent use of medications known to inhibit or induce hepatic enzyme cytochrome P450 (CYP) 3A4\n* Barriers to fine needle aspiration sampling of breast adipose, including breast implants, history of radiation to both breasts, bilateral mastectomies, and/or insufficient breast adipose tissue for adequate fine needle aspiration (FNA) sampling\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements\n* Chronic use of any herbal or dietary supplement containing curcumin or curcuminoids within the 3 months prior to entry on the study or any other supplements that might interact with NEC\n* Known sensitivity or allergy to turmeric spices or curry\n* Dietary intake of large amounts of curry, turmeric spices or black pepper on a regular basis\n* Subjects on a standing regimen of full dose aspirin (\\>= 325 mg/day), non-steroidal anti-inflammatory drug (NSAID)s or NSAID-containing products",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}